Oncotarget
AUTHOR INSIGHT, COMMUNITY NEWS & EVENTS BY ONCOTARGET:
- Rare Laryngeal Leiomyosarcoma Successfully Treated with Surgery and Adjuvant Chemotherapy
A new case report was published in Volume 17 of Oncotarget on May 4, 2026, titled “Laryngeal leiomyosarcoma: A rare case report and literature review.” - Agentic AI Systems May Transform Nutritional Care in Oncology
A new editorial was published in Volume 17 of Oncotarget on May 4, 2026, titled “Artificial intelligence in nutritional oncology: From isolated screening tools to agentic intervention systems.” - Rare Dual-Mutation GIST Responds to Targeted Therapy, Challenging Established Tumor BiologyA new case report was published in Volume 17 of Oncotarget on May 4, 2026, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.”
ABOUT DR. MIKHAIL (MISHA) BLAGOSKLONNY:
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time.
Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy.
Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true.
Read the full tribute to Dr. Blagosklonny | @Blagosklonny
ABOUT ONCOTARGET.NET:
Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget, an open access biomedical journal dedicated to publishing the latest oncology-focused, peer-reviewed research papers. Here, readers will also find information about community news and events sponsored by Oncotarget.
For the latest summaries of new and trending Oncotarget papers,visit Oncotarget.org or ImpactJournals.com. Impact Journals is Oncotarget’s academic publisher. Read about our rigorous Scientific Integrity Process.
CONTACT INFORMATION:
To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.